All In Biotech

Free tool

FAERS Monitor: Pivya

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 216483 or its brand name (Pivya, Pivmecillinam Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

188

Serious

184

98% of reports

Hospitalization

84

Death reported

19

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • malaise20
  • confusional state19
  • urinary incontinence13
  • decreased appetite12
  • drug interaction12
  • diarrhoea11
  • headache11
  • rash11
  • acute kidney injury10
  • hyponatraemia9
  • balance disorder8
  • decreased interest8
  • hypersomnia8
  • lip swelling8
  • muscular weakness8

Reports by year received

View as table
YearReports
20071
20091
20102
20112
20128
20141
20157
201639
20176
201817
201940
202021
202139
20264

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,971 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
decreased interestSignal8152.077.11,053
urinary incontinenceSignal1349.129.1566
hypersomniaSignal831.215.9205
lip swellingSignal826.913.6175
hyponatraemiaSignal917.99.5127
confusional stateSignal1913.28.6203
balance disorderSignal810.45.359
drug interactionSignal128.54.972
muscular weaknessSignal87.94.042
acute kidney injurySignal107.34.049
decreased appetiteSignal125.83.343
malaiseSignal205.13.463
rashSignal112.81.611
headache112.01.14
diarrhoea111.91.14

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.